Anti-CTLA-4 synergizes with dendritic cell-targeted vaccine to promote IL-3-dependent CD4
IL-3
anti-CTLA-4
cancer immunotherapy
dendritic cell-targeted cancer vaccine
tumor-infiltrating T cells
Journal
Annals of the New York Academy of Sciences
ISSN: 1749-6632
Titre abrégé: Ann N Y Acad Sci
Pays: United States
ID NLM: 7506858
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
09
11
2017
revised:
09
02
2019
accepted:
15
02
2019
pubmed:
5
4
2019
medline:
12
3
2020
entrez:
5
4
2019
Statut:
ppublish
Résumé
One successful class of cancer immunotherapies, immune checkpoint inhibitory antibodies, disrupts key pathways that regulate immune checkpoints, such as cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). These agents unleash the potency of antigen-experienced T cells that have already been induced as a consequence of the existing tumor. But only 20% of cancers naturally induce T cells. For most cancers, vaccines are require to induce and mobilize T effector cells (T
Identifiants
pubmed: 30945313
doi: 10.1111/nyas.14049
pmc: PMC6557673
mid: NIHMS1012896
doi:
Substances chimiques
CTLA-4 Antigen
0
Cancer Vaccines
0
Ctla4 protein, mouse
0
Interleukin-3
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
62-73Subventions
Organisme : NCI NIH HHS
ID : P50 CA062924
Pays : United States
Organisme : Cancer Research UK
ID : 12100
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : P01 AI081677
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI051573
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI013013
Pays : United States
Organisme : Worldwide Cancer Research
ID : 13-0316
Pays : United Kingdom
Organisme : NCATS NIH HHS
ID : UL1 TR000043
Pays : United States
Informations de copyright
© 2019 New York Academy of Sciences.
Références
J Exp Med. 2000 May 1;191(9):1569-80
pubmed: 10790431
Cancer Gene Ther. 2000 Aug;7(8):1172-8
pubmed: 10975678
Cancer Res. 2001 May 15;61(10):3932-6
pubmed: 11358808
Cancer Res. 2001 Jul 1;61(13):5132-6
pubmed: 11431351
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Cancer Res. 2003 May 1;63(9):2322-9
pubmed: 12727857
J Clin Invest. 2006 Jul;116(7):1935-45
pubmed: 16778987
Science. 2006 Sep 29;313(5795):1972-5
pubmed: 16931720
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3967-72
pubmed: 17360461
Nat Med. 2008 Jan;14(1):28-36
pubmed: 18157142
Science. 2008 May 9;320(5877):807-11
pubmed: 18467591
Cell Cycle. 2008 Aug 15;7(16):2452-5
pubmed: 18719382
J Exp Med. 2008 Sep 1;205(9):2125-38
pubmed: 18725522
J Exp Med. 2008 Sep 29;205(10):2221-34
pubmed: 18794336
J Immunol. 2008 Nov 1;181(9):6109-16
pubmed: 18941200
Clin Cancer Res. 2009 Jan 1;15(1):390-9
pubmed: 19118070
Clin Cancer Res. 2009 Jul 15;15(14):4521-8
pubmed: 19567593
J Exp Med. 2009 Aug 3;206(8):1717-25
pubmed: 19581407
Ann N Y Acad Sci. 2009 Sep;1174:6-17
pubmed: 19769731
Indian J Community Med. 2008 Jul;33(3):156-9
pubmed: 19876475
J Vis Exp. 2010 Jan 28;(35):null
pubmed: 20110936
Sci Transl Med. 2010 Feb 3;2(17):17ra10
pubmed: 20371478
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Clin Cancer Res. 2011 Jun 15;17(12):4101-9
pubmed: 21558401
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
Oncogene. 2011 Dec 15;30(50):4930-40
pubmed: 21643009
J Clin Invest. 2012 Oct;122(10):3718-30
pubmed: 22945631
N Engl J Med. 2016 Nov 10;375(19):1845-1855
pubmed: 27717298
Clin Cancer Res. 2019 Feb 15;25(4):1233-1238
pubmed: 30054281
J Clin Invest. 2018 Aug 1;128(8):3209-3218
pubmed: 30067248
Clin Cancer Res. 2019 Feb 15;25(4):1130-1132
pubmed: 30291135
J Clin Invest. 2019 Jan 2;129(1):46-47
pubmed: 30507614
Cancer Res. 1984 Feb;44(2):717-26
pubmed: 6692374
Science. 1995 Nov 10;270(5238):985-8
pubmed: 7481803
Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11137-41
pubmed: 7504295
Blood. 1995 Jul 1;86(1):176-82
pubmed: 7540883
J Clin Invest. 1993 Jun;91(6):2887-92
pubmed: 7685775
Eur J Cancer. 1994;30A(12):1797-803
pubmed: 7880609
Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10399-404
pubmed: 8816812
Immunol Cell Biol. 1996 Feb;74(1):1-7
pubmed: 8934648
Semin Oncol. 1997 Feb;24(1 Suppl 4):S2-7
pubmed: 9122730
Cancer Res. 1997 Sep 15;57(18):3899-903
pubmed: 9307268
Int J Cancer. 1997 Oct 21;74(5):492-501
pubmed: 9355970
Blood. 1998 Feb 1;91(3):778-83
pubmed: 9446636
Cancer Res. 1998 Aug 15;58(16):3491-4
pubmed: 9721846
Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11354-9
pubmed: 9736740
J Immunol. 1998 Oct 1;161(7):3347-56
pubmed: 9759851